Arkolith/Insider Trading/SPRY/Form 4

Chakma Justin

Chief Business OfficerARS Pharmaceuticals, Inc. (SPRY) · full profile →Form 4 · filed Nov 14, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.5M
Net Open-Market Flow
-$1.5M
Transactions
4
3 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 12, 2025Sell(S)136K$8.86$1.2M0
Nov 12, 2025Sell(S)30K$8.91$267K136K
Nov 12, 2025Option exercise(M)30K$0.84$25K166K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 12, 2025Option exercise(M)30K—$089K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001951238-25-000005) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML